Kaye Scholer Advises Novartis in Exclusive Global Licensing and Research Collaboration with Regenerex

September 10, 2013

New York: Kaye Scholer client Novartis has entered into an exclusive global licensing and research collaboration agreement with biopharmaceutical company Regenerex LLC for the use of the company’s innovative Facilitating Cell Therapy (FCRx) platform.

FCRx will broaden the current Novartis cell therapy portfolio, which includes two novel cell therapy platforms initially being investigated in hematological malignancies. For additional information, please see Novartis’ official press release announcing the agreement.

Novartis was advised by a Kaye Scholer team that included Partners Adam Golden, David Barr and Andres Liivak, Counsel William Lonergan and Associate Megan Burke.

Email Disclaimer